Latest News on IART

Financial News Based On Company


Advertisement
Advertisement

Integra Lifesciences Holdings Corp (IL3.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance

https://sg.finance.yahoo.com/quote/IL3.MU/analyst-insights/
This article provides analyst insights, price targets, and recommendations for Integra Lifesciences Holdings Corp (IL3.MU). Several firms, including UBS, Truist Securities, Citigroup, BMO Capital, Wells Fargo, and Citizens, maintained their ratings for the company on various dates in late October 2026. The stock was trading at 13.10 EUR with no change at market close on November 13, 2026.

Integra Lifesciences Holdings Corp (IL3.MU) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/IL3.MU/fair-value/
The article provides a snapshot of Integra Lifesciences Holdings Corp (IL3.MU) stock information, including its current price, a slight gain, and links to news, research, charts, and financial data. It also promotes a premium feature for fair value analysis to assist with investment decisions. The quote displayed is delayed from the Munich exchange.

Integra Lifesciences Holdings Corp (IL3.MU) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/IL3.MU/fair-value/
This page provides current stock information for Integra Lifesciences Holdings Corp (IL3.MU) on the Munich exchange, including its delayed quote, recent performance, and key financial statistics. As of 8:02:45 CET, the stock was trading at 13.00 EUR, up 3.17%. The article also presents performance comparisons against the S&P 500 benchmark across various timeframes.

Integra Lifesciences Holdings Corp (IL3.MU) Seasonal returns chart

https://uk.finance.yahoo.com/quote/IL3.MU/seasonality/
This article provides a seasonal returns chart for Integra Lifesciences Holdings Corp (IL3.MU), showing the average monthly price return from 2016 to 2026. The stock is currently trading at 12.60 EUR, up 4.13%.

Integra Lifesciences Holdings Corp (IL3.MU) Seasonal returns chart

https://sg.finance.yahoo.com/quote/IL3.MU/seasonality/
The article provides a seasonal returns chart for Integra Lifesciences Holdings Corp (IL3.MU), showing the average monthly price return from 2016 to 2026. The stock was trading at 12.80 EUR, down 0.78% at the close on November 6th. The page also displays various global market indices and cryptocurrency prices.
Advertisement

A live webcast will be available for Integra's CFO presentation Monday.

https://www.stocktitan.net/news/IART/integra-life-sciences-to-present-at-the-2026-ubs-global-healthcare-ltfmoijlt97t.html
Integra LifeSciences (Nasdaq: IART) announced that its Chief Financial Officer, Lea Knight, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET. A live webcast of her presentation will be accessible on the company’s investor relations website under "EVENTS & PRESENTATIONS." The company is a global medical technology leader focused on neurosurgery and tissue reconstruction.

Integra LifeSciences Holdings Corporation (IART) Seasonal returns chart

https://uk.finance.yahoo.com/quote/IART/seasonality/
This Yahoo Finance article presents the historical seasonality chart for Integra LifeSciences Holdings Corporation (IART), displaying average monthly price returns from 2016 to 2026. The stock's current price and daily performance are also provided. The article focuses on the historical performance data, offering context for potential investment decisions.

An estimated 13.8 million patients need neurosurgery yearly. Integra will offer hands-on training.

https://www.stocktitan.net/news/IART/integra-life-sciences-to-highlight-hands-on-education-and-uvsxiw5999ai.html
Integra LifeSciences (Nasdaq: IART) will participate in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting, offering interactive educational experiences and hands-on training. The company will showcase its comprehensive neurosurgery portfolio, including dural repair, tissue resection, and neurocritical care technologies, to an estimated 13.8 million patients worldwide who require neurosurgical intervention each year. This initiative underscores Integra's commitment to advancing patient care through innovation, education, and collaboration among neurosurgeons.

Integra LifeSciences Holdings Corporation (IART) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/IART/seasonality/
This article provides a seasonal returns chart for Integra LifeSciences Holdings Corporation (IART), displaying average monthly price returns from 2016 to 2026. The stock's current real-time price on NasdaqGS is 12.75 USD, with a slight decrease of 0.62% at market close. The chart allows users to view historical seasonality over various periods.

Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting

https://www.manilatimes.net/2026/10/30/tmt-newswire/globenewswire/integra-lifesciences-to-highlight-hands-on-education-and-neurosurgery-innovation-at-cns-2026-annual-meeting/2458283
Integra LifeSciences Holdings Corporation announced its participation in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting, where it will showcase its neurosurgery portfolio through interactive educational experiences and hands-on training. The company will host a mobile hands-on laboratory and participate in the CNS Skills Showdown, highlighting technologies such as the Aurora® Surgiscope® System and CUSA® Clarity Ultrasonic Surgical Aspirator System. This initiative aims to foster collaboration and advance patient care within neurosurgery, a field requiring intervention for millions globally each year.
Advertisement

Q3 profit replaces a $5.4M year-earlier loss at Integra LifeSciences (IART).

https://www.stocktitan.net/sec-filings/IART/10-q-integra-lifesciences-holdings-corp-quarterly-earnings-report-67e6c453cc96.html
Integra LifeSciences (IART) reported a net income of $14.9 million for Q3 2026, a significant improvement from a $5.4 million loss in the prior-year period. Revenue also increased to $411.2 million, up from $402.1 million year-over-year. The company completed a refinancing in October 2026, securing new credit facilities and $450.0 million in 9.5% notes, and is actively addressing quality system issues and recovering from a flood at its Cincinnati facility.

Integra LifeSciences' $2.1B Refinancing Merits A Closer Look

https://www.benzinga.com/opinion/26/10/62519682/integra-lifesciences-2-billion-refinancing-merits-a-closer-look
Integra LifeSciences Holdings Corporation completed a $2.1 billion refinancing on October 19, 2026, which involved a reduction in revolving credit, new term-loan principal installments, and the issuance of $450 million in secured notes. This article scrutinizes the details of the refinancing, highlighting the distinction between committed borrowing capacity and issued debt, and analyzing the funding mix, repayment schedules, pricing, and covenant tests. It suggests that a closer look at the funded amounts and their true cost is necessary to understand the full balance-sheet effect, beyond the headline figure.

Integra LifeSciences Edges Past EPS Consensus, But The Cincinnati Flood And Weak Tissue Reconstruction Drive A Guidance Reset

https://finviz.com/news/405587/integra-lifesciences-edges-past-eps-consensus-but-the-cincinnati-flood-and-weak-tissue-reconstruction-drive-a-guidance-reset
Integra LifeSciences reported Q3 adjusted earnings that beat consensus, but revenue missed, and the company issued a guidance reset due to issues including a Cincinnati flood and weakness in its Tissue Reconstruction segment. While Neurosurgery showed strength and cash flow was record-high, concerns remain about growing flood costs, market share loss, contracting margins, and increased debt expenses. The company's future hinges on its execution in restoring manufacturing and relaunching key products.

Form 8K Integra LifeSciences Holdings For: 21 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-integra-lifesciences-holdings-for-21-october-93CH-2747998
This article announces that Integra LifeSciences Holdings filed a Form 8K on October 21, 2026. The filing is a standard regulatory disclosure. It also notes a 6.64% drop in the company's stock (IART).

Integra LifeSciences Reports Q3 2026 Financial Results in Form 8-K Filing

https://kalkinemedia.com/us/news/announcements/integra-lifesciences-reports-q3-2026-financial-results-in-form-8-k-filing
Integra LifeSciences Holdings Corporation submitted a Form 8-K filing on October 21, 2026, announcing its financial performance for the third quarter ended September 30, 2026. The report includes non-GAAP financial metrics and forward-looking guidance on organic revenues and adjusted earnings per diluted share. The company detailed various adjustments to net income, citing charges related to structural optimization, divestitures, acquisitions, and manufacturing transitions.
Advertisement

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

https://www.benzinga.com/trading-ideas/movers/26/10/62462992/12-health-care-stocks-moving-tuesday-s-pre-market-session
This article details the pre-market movements of 12 health care stocks on Tuesday. It lists several gainers, including SCWorx, Integra Lifesciences, and Rapport Therapeutics, with their respective percentage increases and stock prices. The article also identifies losers like China SXT Pharmaceuticals and Scinai Immunotherapeutics, noting their declines.

Integra Announces Completion of Refinancing Transactions

https://finance.yahoo.com/markets/stocks/articles/integra-announces-completion-refinancing-transactions-200500983.html
Integra LifeSciences Holdings Corporation announced the completion of refinancing transactions, including a private offering of $450.0 million in 9.500% senior secured notes due 2033 and an amended and restated credit facility of approximately $1.65 billion. The proceeds from these transactions were used to refinance Integra's existing credit facility and cover associated fees and expenses. These securities were offered privately and are not registered under the Securities Act of 1933.

New research on balloon treatment alongside surgery for chronic ear disease will be presented

https://www.stocktitan.net/news/IART/integra-life-sciences-to-highlight-ent-and-instruments-portfolios-0lv30s67ogau.html
Integra LifeSciences will showcase its ENT and instruments portfolios at the 2026 AAO-HNSF Annual Meeting, including the ACCLARENT AERA® Eustachian Tube Treatment. The company is also sponsoring a presentation by Seilesh C. Babu, M.D., on new clinical research concerning the effects of concurrent Eustachian tube balloon dilation on surgical outcomes in chronic ear disease. This investigator-initiated study will be presented on October 17th.

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

https://finance.yahoo.com/healthcare/articles/integra-lifesciences-highlight-ent-instruments-123900469.html
Integra LifeSciences will participate in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO to showcase its ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment. The company is also sponsoring new clinical research on the effects of Eustachian tube balloon dilation in chronic ear disease. Integra LifeSciences aims to advance clinical evidence and innovation in ENT care and will offer hands-on training for its ACCLARENT AERA® system at its booth.

Integra LifeSciences (IART) Institutional Ownership 2026 $IART

https://www.marketbeat.com/stocks/NASDAQ/IART/institutional-ownership/
This article provides an in-depth look at the institutional ownership of Integra LifeSciences (IART) in 2026, detailing current ownership percentages, and institutional buying and selling activities over the past 12 to 24 months. It lists major institutional shareholders and their share movements, offering insights into which funds are accumulating or divesting IART stock. The data is compiled from quarterly 13F filings submitted to the U.S. Securities and Exchange Commission.
Advertisement

Integra Lifesciences Holdings Corp (IART) Shares Surge 4.0% -- What GF Score of 69 Tells Investors

https://www.gurufocus.com/news/9120190/integra-lifesciences-holdings-corp-iart-shares-surge-40-what-gf-score-of-69-tells-investors
Integra Lifesciences Holdings Corp (IART) shares surged 4.0% to $13.98, trading significantly below its GF Value™ of $20.48, suggesting it is undervalued but with a "Possible Value Trap" warning. The company holds an above-average GF Score™ of 69/100, driven by strong momentum (10/10) but hampered by weak growth (3/10) and financial strength (4/10). Insider buying activity indicates confidence despite ongoing losses and negative cash flow, urging investors to exercise caution and conduct thorough assessments.

Integra prices $450M 9.50% senior secured notes due 2033 to refinance debt

https://www.tradingview.com/news/tradingview:4840242a7cb2b:0-integra-prices-450m-9-50-senior-secured-notes-due-2033-to-refinance-debt/
Integra has announced the pricing of $450 million in 9.500% senior secured notes due 2033 through a private placement. The sale is expected to close around October 19, 2026, and the proceeds, combined with a new credit facility, will be used to refinance existing debt. This refinancing is projected to increase the company's effective interest rate towards the higher end of the previously guided 100-200 basis points increase.

Integra LifeSciences Holdings (IART) Cuts 2026 Revenue Outlook, Is The Stock Below Fair Value?

https://finance.yahoo.com/markets/stocks/articles/integra-lifesciences-holdings-iart-cuts-231827329.html
Integra LifeSciences Holdings (IART) has cut its 2026 revenue outlook and announced a $600 million debt refinancing plan. Despite recent share price volatility, the stock is considered undervalued by many, with a fair value of $27.00 compared to its current price of $13.41, based on expectations of operational stabilization and cost efficiencies. Investors are left to weigh whether to buy into the stock after this reset or await further market reaction.

Integra LifeSciences lowers revenue and earnings outlook for 2026

https://finance.yahoo.com/healthcare/articles/integra-lifesciences-lowers-revenue-earnings-144400074.html
Integra LifeSciences Holdings Corp (NASDAQ:IART) has lowered its 2026 revenue and adjusted earnings guidance due to disruptions caused by July flooding in Cincinnati. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion and adjusted earnings per diluted share of $2.30 to $2.40. Despite the revised outlook, CEO Stuart Essig anticipates strong operating cash flow and improvements in product availability and commercial execution.

INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is

https://www.globenewswire.com/news-release/2026/10/06/3376111/0/en/integra-investigation-alert-bragar-eagel-squire-p-c-is-investigating-integra-lifesciences-holdings-corporation-on-behalf-of-integra-stockholders-and-encourages-investors-to-contact.html
Bragar Eagel & Squire, P.C. is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of its stockholders for potential violations of federal securities laws and unlawful business practices. This investigation follows Integra's announcement of lower-than-expected third-quarter 2026 financial results and reduced full-year revenue guidance, attributed to a flooding event at its Cincinnati facility. The company's stock price declined significantly after the disclosure, leading to the law firm encouraging affected investors to contact them to discuss their legal options.
Advertisement

Before the stock market opens Oct. 21, Integra will release third-quarter results and host a call.

https://www.stocktitan.net/news/IART/integra-life-sciences-to-host-third-quarter-2026-financial-results-s5ezjamuug9k.html
Integra LifeSciences (NASDAQ: IART) will release its third-quarter 2026 financial results before the market opens on October 21, 2026. The company's management team will host a conference call at 8:30 a.m. ET on the same day to discuss the results. A live webcast and replay of the call will be available on the Investors section of Integra LifeSciences' website.

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

https://finance.yahoo.com/healthcare/articles/integra-lifesciences-host-third-quarter-123000674.html
Integra LifeSciences Holdings Corporation announced it will release its third-quarter 2026 financial results on Wednesday, October 21, 2026, before the market opens. The company's management team will host a conference call at 8:30 a.m. ET to discuss the results, with a live webcast available on its investor relations website.

BMO cuts Integra LifeSciences stock price target on facility disruption By Investing.com

https://au.investing.com/news/stock-market-news/bmo-cuts-integra-lifesciences-stock-price-target-on-facility-disruption-93CH-4673254
BMO Capital has lowered its price target for Integra LifeSciences Holdings Corp. (NASDAQ:IART) to $15 from $18 due to greater-than-expected disruption from July flooding at its Cincinnati facility, which impacted its third-quarter 2026 results and full-year guidance. Despite this, InvestingPro suggests the stock is undervalued with a Fair Value of $19.60. This adjustment follows recent Q2 2026 earnings that beat expectations, yet share prices declined amid cautious future projections from analysts like Wells Fargo.

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

https://www.globenewswire.com/news-release/2026/10/06/3375492/1063/en/integra-lifesciences-to-host-third-quarter-2026-financial-results-conference-call-on-october-21-2026.html
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced it will release its third-quarter 2026 financial results on Wednesday, October 21, 2026, before the market opens. The company's management will host a conference call at 8:30 a.m. ET to discuss the results, with a live webcast available on their investor relations website. A replay of the call will also be accessible on the website.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION:

https://www.globenewswire.com/news-release/2026/10/05/3375068/0/en/integra-lifesciences-holdings-corporation-investigation-iart-securities-investors-encouraged-to-contact-kirby-mcinerney-llp-about-their-rights.html
Kirby McInerney LLP is investigating potential claims against Integra LifeSciences Holdings Corporation (NASDAQ: IART) regarding possible federal securities law violations or unlawful business practices. This investigation follows Integra's disclosure of lower-than-expected Q3 2026 revenues and a reduced full-year revenue guidance due to a July flooding event at its Cincinnati facility, which contrasted with prior assurances from the CFO. Following this announcement, Integra's shares declined significantly.
Advertisement

Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook

https://www.benzinga.com/markets/guidance/26/10/62171941/flood-damage-prompts-integra-lifesciences-to-revise-2026-outlook
Integra LifeSciences revised its full-year 2026 guidance downwards following severe July flooding at its Cincinnati manufacturing facility, which caused significant operational disruptions and negatively impacted third-quarter revenue by approximately $7 million. The company anticipates further revenue losses of $15 million to $20 million in the fourth quarter but expects insurance recoveries to offset the financial impact. Integra aims to restore full manufacturing capacity at the site by the second quarter of 2027.

Investigation launched into Integra LifeSciences over delayed flood impact disclosures.

https://pluang.com/en/news-feed/peringatan-investor-integra-lifesciences-penurunan-saham-akibat-banjir-dan
Johnson Fistel, PLLP is investigating Integra LifeSciences for allegedly misleading investors about the financial impact of a flood at its Cincinnati facility. Initially, Integra downplayed the effects on its 2026 revenue and earnings guidance, but later disclosed significant losses and a delayed operational recovery, causing a 21% drop in shares. The investigation aims to determine if management provided inaccurate information regarding the severity and timeline of the disruption.

$450 million in Integra LifeSciences notes carry a 9.5% rate

https://www.stocktitan.net/news/IART/integra-announces-pricing-of-senior-secured-32si7v62oy7o.html
Integra LifeSciences Holdings (IART) announced the pricing of $450 million in senior secured notes with a 9.500% interest rate, maturing in 2033. This offering is part of a larger refinancing initiative. The company plans to use the proceeds, combined with new credit facilities, to refinance existing credit facilities and cover associated fees.

Cincinnati flooding disrupts supply as Integra LifeSciences (IART) cuts its 2026 outlook.

https://www.stocktitan.net/sec-filings/IART/8-k-integra-lifesciences-holdings-corp-reports-material-event-f22c38b03adf.html
Integra LifeSciences (IART) has lowered its 2026 revenue and adjusted EPS outlook due to supply disruptions caused by a July 2026 flood at its Cincinnati manufacturing facility. The company now expects 2026 reported revenue between $1.634 billion and $1.654 billion, and adjusted EPS between $2.30 and $2.40. Integra anticipates the Cincinnati facility to return to full manufacturing operations in the second quarter of 2027, with insurance recoveries expected to mitigate a substantial portion of the earnings impact.

Integra LifeSciences Q3FY26 Results: Guidance cut on flood impact

https://scanx.trade/stock-market-news/companies/integra-lifesciences-q3fy26-results-guidance-cut-flood-impact/52488615
Integra LifeSciences' shares dropped 17% after its preliminary Q3FY26 revenue missed consensus estimates, leading to a cut in its full-year revenue and adjusted EPS guidance. The company attributed the shortfall to a July flooding event at its Cincinnati facility, which is also the subject of a potential securities claims investigation by SueWallSt concerning prior statements made by the CFO. Despite the revenue impact, Integra expects strong cash generation and significant mitigation from insurance recoveries.
Advertisement

Integra LifeSciences cuts 2026 guidance after flooding impact

https://www.investing.com/news/company-news/integra-lifesciences-cuts-2026-guidance-after-flooding-impact-93CH-4929684
Integra LifeSciences (NASDAQ: IART) has revised its full-year 2026 financial guidance downwards due to production disruptions caused by July flooding at its Cincinnati manufacturing facility. The company anticipates third-quarter revenue between $410 million and $412 million, and adjusted earnings per diluted share of $0.55 to $0.59. For the full year, revenue is now projected to be $1.634 billion to $1.654 billion, down from the previous range of $1.654 billion to $1.695 billion, with adjusted earnings per share reduced to $2.30 to $2.40 from $2.40 to $2.50.

(IART) Integra LifeSciences Expects Q3 Revenue Range $410M - $412M, vs. FactSet Est of $416.3M

https://www.marketscreener.com/news/iart-integra-lifesciences-expects-q3-revenue-range-410m-412m-vs-factset-est-of-416-3m-ce785ddad18df424
Integra LifeSciences Holdings Corporation (IART) expects its third-quarter revenue to be in the range of $410 million to $412 million, falling short of FactSet's estimated $416.3 million. This announcement comes alongside other news regarding the company's preliminary Q3 results, lowered full-year guidance, and the launch of a $600 million senior secured term loan. The company's shares experienced an 11% pre-bell drop following the news.

A July flood is expected to cut Integra's fourth-quarter revenue by about $15-$20 million

https://www.stocktitan.net/news/IART/integra-life-sciences-announces-preliminary-third-quarter-results-hso975xm72jy.html
Integra LifeSciences announced preliminary third-quarter results and updated its full-year 2026 guidance, lowering revenue and adjusted EPS expectations due to a July flood at its Cincinnati facility. The flood is anticipated to reduce fourth-quarter revenue by $15 million to $20 million, with full manufacturing operations expected to resume in the second quarter of 2027. Despite the setbacks, Integra expects strong cash generation for the year and anticipates insurance recoveries to mitigate a substantial portion of the financial impact.

Integra LifeSciences lowers revenue and earnings outlook for 2026

https://www.proactiveinvestors.com/companies/news/1099524/integra-lifesciences-lowers-revenue-and-earnings-outlook-for-2026-1099524.html
Integra LifeSciences (NASDAQ:IART) has lowered its 2026 revenue and adjusted earnings per diluted share guidance due to operational disruptions caused by July flooding in Cincinnati. Despite the reduced outlook, CEO Stuart Essig anticipates strong operating cash flow for both the quarter and the full year, alongside improvements in product availability and commercial execution. The company expects property and business interruption insurance to mitigate much of the financial impact, with full manufacturing operations at the Cincinnati facility projected to resume in Q2 2027.

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

https://finance.yahoo.com/healthcare/articles/integra-lifesciences-announces-preliminary-third-120500856.html
Integra LifeSciences (Nasdaq: IART) announced preliminary third-quarter 2026 results and updated its full-year 2026 guidance, citing an impact from a July flooding event at its Cincinnati facility. The company expects third-quarter revenue of $410 million to $412 million and adjusted EPS of $0.55 to $0.59, and has lowered its full-year revenue outlook to $1.634 billion to $1.654 billion and adjusted EPS to $2.30 to $2.40. Despite the reduction, Integra anticipates strong operating cash flow of approximately $190 million to $200 million for the full year and expects insurance recoveries to mitigate much of the financial impact from the Cincinnati facility disruption.
Advertisement

Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry

https://finance.yahoo.com/healthcare/articles/integra-lifesciences-announces-100th-patient-123000283.html
Integra LifeSciences announced the enrollment of its 100th patient in the AERA® Pediatric Registry, a significant step toward its goal of 300 patients. This registry evaluates the Acclarent AERA Eustachian Tube Balloon Dilation System's effectiveness in pediatric patients aged eight and older with obstructive Eustachian tube dysfunction. The AERA system received FDA clearance for its pediatric indication in December 2023, making it the first and only such system for this age group.

A registry tracking an ear treatment for children has enrolled 100 of its planned 300 patients.

https://www.stocktitan.net/news/IART/integra-life-sciences-announces-100th-patient-enrolled-in-aera-xkj0yr03p6c1.html
Integra LifeSciences announced that its AERA Pediatric Registry has enrolled its 100th patient, reaching one-third of its target of 300 patients. This registry evaluates the AERA Eustachian Tube Balloon Dilation System for children aged eight and older with obstructive Eustachian tube dysfunction. The system received FDA clearance for pediatric use in December 2023.

Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026

https://finance.yahoo.com/healthcare/articles/integra-lifesciences-marks-20-years-130500145.html
Integra LifeSciences is celebrating 20 years of its CUSA® technology at the American College of Surgeons (ACS) Clinical Congress 2026. The company will host surgeon-led educational programming focusing on liver surgery, featuring presentations by internationally recognized experts. This initiative aims to advance education and collaboration in liver surgery, a critical field given the high global incidence of liver cancer.

More than 800,000 people are diagnosed with liver cancer yearly. Surgeons will discuss complex liver procedures.

https://www.stocktitan.net/news/IART/integra-life-sciences-marks-20-years-of-cusa-technology-with-liver-43xbr4i4ysb1.html
Integra LifeSciences will showcase its CUSA and MicroFrance technologies at the ACS Clinical Congress 2026, celebrating 20 years of CUSA technology. The event will feature educational programming and discussions led by liver surgeons, focusing on complex liver procedures. This initiative highlights the ongoing importance of collaboration and education in treating conditions like liver cancer, which affects over 800,000 people annually.

Integra LifeSciences (IART) Stock May Be 48% Undervalued On Cash Flow

https://finance.yahoo.com/markets/stocks/articles/integra-lifesciences-iart-stock-may-061538072.html
Integra LifeSciences (IART) stock is currently trading at US$16.02, but analysis suggests it may be significantly undervalued based on its future cash flow generation. Despite a 77.3% decline over the past five years, analysts forecast a recovery in free cash flow, which, when discounted, indicates an intrinsic value substantially higher than the current share price. This discrepancy suggests the market isn't fully pricing in the anticipated turnaround in the company's cash flow performance.
Advertisement

Integra LifeSciences to Present at the 2026 Wells Fargo

https://www.globenewswire.com/news-release/2026/09/04/3356591/1063/en/integra-lifesciences-to-present-at-the-2026-wells-fargo-healthcare-conference-and-the-2026-morgan-stanley-healthcare-conference.html
Integra LifeSciences Holdings Corporation announced that its executives will present at two upcoming healthcare conferences. Lea Knight, CFO, and Michael McBreen, CCO, will present at the 2026 Wells Fargo Healthcare Conference, and Stuart Essig, Chairman and CEO, will present at the 2026 Morgan Stanley Healthcare Conference. Live webcasts of these presentations will be available on the company's investor relations website.

Integra LifeSciences to present at Wells Fargo and Morgan Stanley healthcare conferences

https://scanx.trade/stock-market-news/companies/integra-lifesciences-present-wells-fargo-morgan-stanley-healthcare/50074226
Integra LifeSciences Holdings Corporation announced that its CFO Lea Knight and CCO Michael McBreen will present at the Wells Fargo Healthcare Conference on September 9, 2026, while CEO Stuart Essig will speak at the Morgan Stanley Healthcare Conference on September 15, 2026. These presentations offer investors an opportunity to engage with Integra's leadership team regarding its business strategy and operational updates. Live webcasts of both sessions will be available on the company's investor relations website.

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

https://finance.yahoo.com/healthcare/articles/integra-lifesciences-present-2026-wells-131500981.html
Integra LifeSciences Holdings Corporation announced that its executives, Lea Knight and Michael McBreen, will present at the 2026 Wells Fargo Healthcare Conference on September 9, 2026. Additionally, Stuart Essig will present at the 2026 Morgan Stanley Healthcare Conference on September 15, 2026. Live webcasts of these presentations will be available on the company's investor relations website.

Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis (NASDAQ:IART)

https://seekingalpha.com/article/4942526-integra-lifesciences-strong-q2-2026-results-support-recovery-thesis
Integra LifeSciences (IART) reported strong Q2 2026 results, beating earnings estimates and expanding margins, reinforcing its recovery thesis. The company's specialty surgery segment drove revenue growth, and while tissue reconstruction saw declines, the successful PriMatrix relaunch and upcoming SurgiMend reintroduction are expected to offset this. Management aims to reduce leverage to 2.5–3.5x by year-end 2026, and IART trades at a significant EV/EBITDA discount, presenting potential for earnings upside through product relaunches.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Integra LifeSciences (IART) Investors of Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm's Attorneys

https://www.newsfilecorp.com/release/181261?lang=fr
Hagens Berman is reminding Integra LifeSciences (IART) investors of a pending securities fraud class action lawsuit. The litigation focuses on Integra's alleged false and misleading statements regarding FDA violations at its Boston Facility, which led to a product recall and production halt. Investors who suffered substantial losses are encouraged to contact Hagens Berman to discuss their legal rights.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement